Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations

The authors describe the differences between patients with essential thrombocythemia who have either JAK2- or CALR-mutations. Mutations in JAK2 or CALR are present in about 50% and 25% of patients with essential thrombocythemia, respectively, and these mutations are thought to drive myeloproliferative neoplasms (MPNs). CALR and JAK2 mutations are mutually exclusive in MPNs.

 Ann Lab Med

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.